Результаты поиска

Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.

Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of 70 years. The challenge in treating older patients is to accurately identify 'fit' patients that can tolerate more intensive treatment to maximize disease control, while simultaneously identifying vulnerable or 'frail' patients who may develop toxicity with significant morbidity and mortality, requiring different treatment options or dose modification. Multiple frailty scores have been devised for multiple myeloma over the years in newly-diagnosed patients. This paper

Совпадение в полном тексте источника
… Age and ECOG-PS are routinely measured by oncologists. The NT pro-BNP level is a blood test which is available in most laboratories; however, the sensitivity and specificity of the assay differs across different labs and may be variable. … Additionally, the variables used to calculate frailty consist of multiple objective and subjective tools such as timed up and go test and fitness respectively which oncologists do not routinely utilize; however are overall simple tests to conduct. …

Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.

BACKGROUND: Guidelines recommend bone-modifying agents (BMAs) for all patients initiating treatment for myeloma. We examined adherence to this recommendation, and BMA effectiveness in the era of bortezomib/lenalidomide-based therapy among Medicare beneficiaries. METHODS: From the linked Surveillance, Epidemiology, and End Results-Medicare registry, we selected beneficiaries receiving anti-myeloma chemotherapy in 2007-2013. We matched BMA recipients (within 90 days of first chemotherapy) to nonrecipients using a propensity score, balancing patient-, disease-, and therapy-related confounders. C

Совпадение в полном тексте источника
… The 4% incidence of ONJ observed in our claims‐based analysis mirrors rates seen in clinical trials. 7 , 8 , 32 Another recent study observed a low rate of BMA initiation in an academic practice (68%), which was substantially improved through a collaboration between the oncologists and clinical pharmacists … Oncologist. 2011;16:651‐662. 38. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double‐blind, randomised controlled trial. Lancet Oncol. 2010;11:973‐982. 39. …

Fit & strong! Promotes physical activity and well-being in older cancer survivors.

IntroductionPhysical activity reduces fatigue and depression while improving quality of life in cancer survivors. Exercise is generally considered safe and is recommended to survivors of all ages. Despite the high prevalence of cancer in the elderly, few studies address physical activity interventions targeting this older population. Fit & Strong! is an evidence-based physical activity program shown to improve level of physical activity, exercise-self-efficacy, and mood in older adults with osteoarthritis. This study tests the feasibility and short-term impact of the Fit & Strong! exercise pro

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.

ObjectivesA multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.Materials and methodsMales (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance

Совпадение в полном тексте источника
… Zoledronic acid needs to be an integral part of a multi-disciplinary treatment plan for bone metastasis resulting from prostate cancer, and should be the fruit of the collaboration between urologists, oncologists, radiologists, and pain management specialists ( Berenson 2005 ). … Oncologist. 2005;10:52–62. doi: 10.1634/theoncologist.10-1-52. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol. 2001;166:2023–31. Boissier S, Ferreras M, Peyruchaud O, et al. …

Haemato-oncology and burnout: an Italian survey.

This cross-sectional survey aimed to evaluate the prevalence of burnout and estimated psychiatric disorders among haemato-oncology healthcare professionals in Italy. The aspects of work that respondents perceive as stressful and satisfying have also been examined. The assessments were made using the Maslach Burnout Inventory (MBI), General Health Questionnaire and a study-specific questionnaire. Logistic regression models were applied to show associations between different sources of work-related stress and burnout. Three hundred and eighty-seven out of 440 (87.95%) returned their questionnair

Совпадение в полном тексте источника
… Am J Respir Crit Care Med 175 : 686 –692 17234905 10.1164/rccm.200608-1184OC Fallowfield L, Jenkins V, Farewell V, Saul J, Duffy A, Eves R ( 2002 ) Efficacy of a cancer research UK communication skills training model for oncologists: a randomized controlled trial . … Results of a random survey of 1000 oncologists . J Clin Oncol 9 : 1916 –1920 1919641 10.1200/JCO.1991.9.10.1916 Wilkinson P ( 1993 ) Mental health problems at work . BMJ 306 : 1082 –1083 8495151 10.1136/bmj.306.6885.1082 PMC1677531 …

Research trends of acupuncture therapy for painful peripheral nervous system diseases from 2004 to 2023: a bibliometric and meta-analysis.

BackgroundPeripheral nervous system diseases (PNSD) have represented a major global health burden, leading to significant economic impacts and diminished productivity. This bibliometric analysis was performed to summarize the current research trends and hotspots over the past two decades, aiming to provide a comprehensive perspective for future research.MethodsAll data were sourced from the Web of Science Core Collection (WoSCC) on March 1, 2024, for publications between January 1, 2004, and December 31, 2023. Data visualization and analyses, including descriptive statistics, co-occurrence map

Prevention of cancer-therapy related cardiac dysfunction.

PURPOSE OF REVIEW: Introduction of modern cancer therapies has led to increased survival of affected patients. With this advantage, the incidence of cancer therapy-related cardiac dysfunction (CTRCD) has increased and reasonable prevention strategies become necessary. This review outlines the major approaches to limit development and progression of CTRCD. RECENT FINDINGS: A broad range of cancer therapies can provoke CTRCD ranging from mild asymptomatic forms to severe heart failure. Profound cardiological assessment of cardiovascular comorbidities before initiation of cancer therapy allows i

Совпадение в полном тексте источника
… Recent studies highlighted the complex interplay between cardiovascular conditions and cancer diseases, underscoring the importance of interdisciplinary cooperation of oncologists and cardiologists in cancer treatment plans [ 6 ]. … Discontinuation of cancer therapy depends on the level of CTRCD severity and relies on interdisciplinary decision between oncologists and cardiologists [ 4 , 96 ]. Therapy of CTRCD follows the guidelines for treatment of heart failure [ 26 ]. …

Health- related quality of life after surgery for spinal metastases.

BACKGROUND: Surgery for spinal metastases is almost always palliative and part of a multidisciplinary approach that has determined a significant increase of life expectancy in the last decade; thus, an improvement in health-related quality of life (HRQOL) is the main goal of the treatment of spinal metastases. We report here the results of a prospective study conducted with the aim of evaluating the impact of spinal surgery on HRQOL, measured by Patient-Reported Outcomes Measures (PROMs). We analyzed clinical outcomes (ambulatory status, performance status, pain, neurological status) and HRQOL

Совпадение в полном тексте источника
… The indication for surgical treatment of spinal metastases should be evaluated by a multidisciplinary approach [7] , including spine surgeons, oncologists, radiotherapists, interventional radiologists. … This assessment can be achieved with an individualized discussion with the patient’s oncologist, and it should be focused on whether the patient would have an opportunity to adequately recover from the indicated surgery in order to continue systemic therapy. …

How does medication-related osteonecrosis of the jaw (MRONJ) influence the health-related quality of life after surgery?

BACKGROUND: Medication-Related Osteonecrosis of the Jaw (MRONJ), an established side effect of antiresorptive and antiangiogenic medication, could sometimes require surgical intervention, such as decortication. The objectives of this retrospective patient survey study were to evaluate the effect of surgical treated MRONJ on health-related quality of life (QoL) and to assess the awareness of the risk of MRONJ. METHODS: The MRONJ-related QoL in both cancer and osteoporosis patients was determined in four different time periods after surgery applying the European Organisation for Research and Tr

Совпадение в полном тексте источника
… Only a third of the patients that felt adequately informed named their dentist and only a tenth their oncologist as an informer about MRONJ. The rest was informed by an oral and maxillofacial surgent. … To achieve the best outcome for patients with MRONJ, a multidisciplinary approach is crucial and should involve dentists, nurses, primary care physicians, oncologists, oral and maxillofacial surgeons and the patient. …

Optimizing Care: Integrative Oncology in Myeloproliferative Neoplasm.

Purpose of reviewMyeloproliferative neoplasm (MPN) burdens the lives of those affected. MPN patients endure significant impacts on their physical, psychological, and social well-being. While pharmacological interventions offer some disease and symptom control, they often have unfavorable side effects. This review explores the potential of Integrative Oncology (IO) therapies in managing MPNs and their associated symptoms.Recent findingsIO is dedicated to augmenting conventional treatments through integrating interventions targeting the mind, body, nutrition, supplements, and other supportive ca

Совпадение в полном тексте источника
… Given the growing interest in these interventions, it is imperative that oncologists facilitate open communication with patients and guide them toward reputable integrative care resources. … Cassileth BR Deng G Complementary and alternative therapies for cancer Oncologist 2004 9 1 80 89 10.1634/theoncologist.9-1-80 14755017 Cassileth BR, Deng G. Complementary and alternative therapies for cancer. Oncologist. 2004;9(1):80–9. 14755017 10.1634/theoncologist.9-1-80 82. …

Can electronic assessment tools improve the process of shared decision-making? A systematic review.

BackgroundPatient involvement in decision-making plays a prominent role in improving the quality of healthcare. Despite this, shared decision-making is not routinely implemented. However, electronic assessment tools that capture patients' history, symptoms, opinions and values prior to their medical appointment are used by healthcare professionals during patient consultations to facilitate shared decision-making.ObjectiveTo assess the effectiveness of electronic assessment tools to improve the shared decision-making process.MethodA systematic review was conducted following PRISMA guidelines. P

Antitumoral Agent-Induced Constipation: A Systematic Review.

BackgroundConstipation is a common symptom in patients receiving antitumoral treatment. The mechanisms underlying antitumoral agent-induced constipation (ATAIC) are poorly defined. This systematic review aimed to analyze and synthesize the available information related to the prevalence, etiology, and treatment of ATAIC.MethodsA systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted. The review included human studies written in English, French, or Spanish involving patients with cancer and containing information abou

Совпадение в полном тексте источника
… Both medical oncologists provided valuable assistance in understanding the mechanism of action of antitumoral treatments. Author Contributions A.C.-B. performed the search. A.C.-B. and J.J. … Oncologist. 2018;24:762–771. doi: 10.1634/theoncologist.2018-0590. 18. Mao T., Cheng Q., Liu X., Chen Y. Effect of electrical stimulation on gastrointestinal symptoms in lung cancer patients during chemotherapy: A randomized controlled trial. Asia-Pac. J. Oncol. …

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.

BACKGROUND: Carboplatin and paclitaxel (CT) is one of the standard chemotherapy regimens used in various tumor types. Preclinical models have suggested that selinexor, a first-in-class oral potent selective inhibitor of nuclear export Exportin-1, and CT exerts antitumor activity in multiple malignancies. METHODS: This was a single-center, multi-arm phase Ib study utilizing a "basket type" expansion. CT and selinexor was employed as one of the 13 parallel arms. Advanced relapsed/refractory solid tumors following standard therapy or where the addition of selinexor to standard regimens deemed ap

Совпадение в полном тексте источника
… Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR American Journal of Roentgenology 195 (2):281–289. 10.2214/ajr.09.4110 10.2214/AJR.09.4110 20651182 21. … Oncologist 24(7):887-e416. 10.1634/theoncologist.2019-0231 30996012 10.1634/theoncologist.2019-0231 PMC6656474 25. …

Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.

Immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1) and its ligand PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are involved in T cell-mediated immune response augmentation and promote anti-tumor immunity. Cancer patients treated with combination of immunotherapy, chemotherapy, radiotherapy, and targeted therapy exhibit superior clinical outcomes and tolerance compared with patients treated with monotherapies. However, immutherapy is associated with several concomitant immune-related adverse events (irAEs). For instance, IrAEs interfere

Cancer in Lahore, Pakistan, 2010-2019: an incidence study.

ObjectivesTo study the cancer incidence rates over 10 years (2010-2019), in Lahore, Pakistan.DesignAn incidence study.SettingThe population-based Punjab Cancer Registry was established in 2005 in Lahore, which is the provincial metropolis of the province of Punjab (five rivers), and is located in the northeast region of Pakistan. The coordinating office of the Registry is located within Shaukat Khanum Memorial Cancer Hospital and Research Center. Both the active and passive forms of data collection are used.ParticipantsResidents of the district of Lahore diagnosed with cancer. The average annu

Совпадение в полном тексте источника
… Despite this, there is a dearth of trained oncologists, and most patients with cancer never get to see a medical oncologist throughout their treatment. 58 The aforementioned issues are compounded by the fact that Pakistan being a populous country, the delivery of healthcare continues to be complex with … Once the incidence and prevalence are estimated in larger populations, logistical issues such as training of oncologists, surgeons, pathologists, nurses and public health officers, along with the construction of an adequate number of hospitals could be dealt with as a continuum of care. …

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol.

BackgroundDespite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Histone-deacetylase inhibitors (HDACi) have shown activity in combination with chemotherapy in the treatment of solid tumors. Owing to its HDACi activity and its safe use for epileptic disorders, valproic acid (VPA) is a good candidate for anticancer therapy that we have largely explored preclinically tra

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.

PurposeLymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases.MethodsThis comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T c

Designing optimal allocations for cancer screening using queuing network models.

Cancer is one of the leading causes of death, but mortality can be reduced by detecting tumors earlier so that treatment is initiated at a less aggressive stage. The tradeoff between costs associated with screening and its benefit makes the decision of whom to screen and when a challenge. To enable comparisons across screening strategies for any cancer type, we demonstrate a mathematical modeling platform based on the theory of queuing networks designed for quantifying the benefits of screening strategies. Our methodology can be used to design optimal screening protocols and to estimate their

Strategies to Mitigate Cisplatin-Induced Ototoxicity: A Literature Review of Protective Agents, Mechanisms, and Clinical Gaps.

BackgroundCisplatin, a widely used chemotherapeutic agent, is associated with significant ototoxicity, leading to progressive and irreversible sensorineural hearing loss in up to 93% of patients. Cisplatin generates reactive oxygen species (ROS) in the cochlea, activating apoptotic and necroptotic pathways that result in hair cell death. Inflammatory processes and nitrative stress also contribute to cochlear damage.MethodsThis literature review was conducted to explore the mechanisms underlying cisplatin-induced ototoxicity and evaluate protective strategies, including both current and emergin

Совпадение в полном тексте источника
… A team-based approach involving oncologists, audiologists, and nurses is crucial for effectively managing ototoxicity in cancer patients: Oncologists play a central role in ototoxicity management as the primary source of information for patients about the potential ototoxic effects of chemotherapy [ … Perceptions of Oncologists at Two State Hospitals in Gauteng Regarding the Ototoxic Effects of Cancer Chemotherapy: A Pilot Study. Afr. J. Pharm. Pharmacol. 2009;3:307–318. 102. …

Temporal trends in Hematopoietic Stem Cell Transplantation in Argentina: regional differences that mirror the global reality.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.